Top-Rated StocksTop-RatedNASDAQ:VRDN Viridian Therapeutics (VRDN) Stock Price, News & Analysis → The asset beating inflation by 4x (From Colonial Metals) (Ad) Free vrdn Stock Alerts $15.40 +0.82 (+5.62%) (As of 05/3/2024 ET) Add Compare Share Share Today's Range$15.01▼$15.5050-Day Range$12.70▼$20.1752-Week Range$10.93▼$28.35Volume758,034 shsAverage Volume782,572 shsMarket Capitalization$982.83 millionP/E RatioN/ADividend YieldN/APrice Target$36.60 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Viridian Therapeutics alerts: Email Address Viridian Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside137.7% Upside$36.60 Price TargetShort InterestBearish15.25% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($4.39) to ($4.29) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.54 out of 5 starsMedical Sector843rd out of 904 stocksMedical Laboratories Industry17th out of 19 stocks 3.5 Analyst's Opinion Consensus RatingViridian Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 10 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageViridian Therapeutics has only been the subject of 4 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted15.25% of the outstanding shares of Viridian Therapeutics have been sold short.Short Interest Ratio / Days to CoverViridian Therapeutics has a short interest ratio ("days to cover") of 10.8, which indicates bearish sentiment.Change versus previous monthShort interest in Viridian Therapeutics has recently increased by 2.75%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldViridian Therapeutics does not currently pay a dividend.Dividend GrowthViridian Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VRDN. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 4 news articles for Viridian Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 11 people have searched for VRDN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows8 people have added Viridian Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 14% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Viridian Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.43% of the stock of Viridian Therapeutics is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Viridian Therapeutics are expected to grow in the coming year, from ($4.39) to ($4.29) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Viridian Therapeutics is -2.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Viridian Therapeutics is -2.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioViridian Therapeutics has a P/B Ratio of 3.44. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap ProfitsClaim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.Secure Your Spot Now About Viridian Therapeutics Stock (NASDAQ:VRDN)Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.Read More VRDN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VRDN Stock News HeadlinesMay 3, 2024 | businesswire.comViridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 29, 2024 | businesswire.comViridian Therapeutics to Webcast First Quarter 2024 Financial Results on May 8, 2024May 5, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.April 29, 2024 | americanbankingnews.comViridian Therapeutics, Inc. (NASDAQ:VRDN) Given Consensus Recommendation of "Buy" by AnalystsApril 13, 2024 | fool.comViridian Therapeutics (NASDAQ: VRDN)April 6, 2024 | markets.businessinsider.comBuy Rating Affirmed for Viridian Therapeutics Amidst TED Treatment Market PotentialApril 4, 2024 | businesswire.comViridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 29, 2024 | prnewswire.comVIRIDIAN SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Viridian Therapeutics, Inc. (VRDN) and Encourages Investors to Contact the FirmMay 5, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.March 25, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Viridian Therapeutics (VRDN), OmniAb (OABI) and Vericel (VCEL)March 20, 2024 | markets.businessinsider.comBuy Rating Endorsed for Viridian Therapeutics’ VRDN Treatments Based on Superior Efficacy and Dosing Advantages in TED MarketMarch 20, 2024 | markets.businessinsider.comUnveiling 4 Analyst Insights On Viridian TherapeuticsMarch 19, 2024 | investorplace.comFinding the Next Big Winners: 3 Stocks You Can Snag for Under $20March 16, 2024 | finance.yahoo.comVRDN Sep 2024 20.000 putMarch 16, 2024 | finance.yahoo.comVRDN Apr 2024 20.000 putMarch 15, 2024 | stockhouse.comSHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Viridian Therapeutics, Inc. (VRDN) and Encourages Investors to Contact the FirmMarch 9, 2024 | nasdaq.comVRDN Makes Bullish Cross Above Critical Moving AverageMarch 6, 2024 | businesswire.comViridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 5, 2024 | finance.yahoo.comViridian Therapeutics to Participate in the Leerink Partners Global Biopharma ConferenceMarch 1, 2024 | markets.businessinsider.comBuy Rating Affirmed for Viridian Therapeutics Amid Strong Clinical Progress and Market PotentialFebruary 29, 2024 | markets.businessinsider.comBuy Rating on Viridian Therapeutics Backed by Pipeline Progress and Phase 3 Trial PotentialFebruary 29, 2024 | finance.yahoo.comViridian Therapeutics Full Year 2023 Earnings: Misses ExpectationsFebruary 28, 2024 | markets.businessinsider.comBuy Rating Affirmed for Viridian Therapeutics Amid Strong Drug Pipeline Progress and Robust Financial PositionFebruary 28, 2024 | msn.comViridian Therapeutics GAAP EPS of -$1.35February 27, 2024 | businesswire.comViridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial ResultsFebruary 22, 2024 | markets.businessinsider.comSHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Viridian Therapeutics, Inc. (VRDN)February 17, 2024 | finance.yahoo.comVRDN Mar 2024 30.000 putSee More Headlines Receive VRDN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Viridian Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/27/2024Today5/05/2024Next Earnings (Confirmed)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryN/A Current SymbolNASDAQ:VRDN CUSIPN/A CIK1590750 Webwww.viridiantherapeutics.com Phone(617) 272-4600Fax760-537-4101Employees94Year FoundedN/APrice Target and Rating Average Stock Price Target$36.60 High Stock Price Target$46.00 Low Stock Price Target$25.00 Potential Upside/Downside+137.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($5.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-237,730,000.00 Net Margins-75,711.48% Pretax Margin-75,711.46% Return on Equity-121.80% Return on Assets-61.06% Debt Debt-to-Equity Ratio0.09 Current Ratio18.26 Quick Ratio18.26 Sales & Book Value Annual Sales$310,000.00 Price / Sales3,170.41 Cash FlowN/A Price / Cash FlowN/A Book Value$4.48 per share Price / Book3.44Miscellaneous Outstanding Shares63,820,000Free Float62,909,000Market Cap$982.83 million OptionableOptionable Beta1.14 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Stephen F. Mahoney J.D. (Age 53)MBA, CEO, President & Director Dr. Eric N. Olson Ph.D.Co-Founder & Chairman of Scientific Advisory BoardDr. Michael R. Bristow M.D. (Age 79)Ph.D., Co-Founder & Member of the Scientific Advisory Board Dr. Marvin H. Caruthers Ph.D. (Age 84)Co-Founder & Scientific Advisory Board Member Mr. Vahe Bedian Ph.D.Co-Founder & Scientific AdvisorMr. Seth HarmonSenior VP of Finance and Accounting, Principal Financial & Accounting OfficerMr. Thomas W. Beetham J.D. (Age 54)MBA, Chief Operating Officer Ms. Jennifer Tousignant J.D.Chief Legal OfficerMr. John A. JordanVice President of Investor Relations & Corporate CommunicationsMr. Anthony Casciano (Age 47)Chief Commercial Officer More ExecutivesKey CompetitorsFulgent GeneticsNASDAQ:FLGTCastle BiosciencesNASDAQ:CSTLCelcuityNASDAQ:CELCCareDxNASDAQ:CDNASera PrognosticsNASDAQ:SERAView All CompetitorsInsiders & InstitutionsMirae Asset Global Investments Co. Ltd.Bought 1,135 shares on 5/1/2024Ownership: 0.045%Principal Financial Group Inc.Bought 1,058 shares on 4/29/2024Ownership: 0.019%Rosalind Advisors Inc.Sold 60,332 shares on 4/25/2024Ownership: 0.478%Hennion & Walsh Asset Management Inc.Bought 34,040 shares on 4/17/2024Ownership: 0.175%Wellington Management Group LLPSold 23,551 shares on 3/5/2024Ownership: 0.306%View All Insider TransactionsView All Institutional Transactions VRDN Stock Analysis - Frequently Asked Questions Should I buy or sell Viridian Therapeutics stock right now? 10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Viridian Therapeutics in the last twelve months. There are currently 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" VRDN shares. View VRDN analyst ratings or view top-rated stocks. What is Viridian Therapeutics' stock price target for 2024? 10 equities research analysts have issued 12 month price targets for Viridian Therapeutics' stock. Their VRDN share price targets range from $25.00 to $46.00. On average, they anticipate the company's stock price to reach $36.60 in the next year. This suggests a possible upside of 137.7% from the stock's current price. View analysts price targets for VRDN or view top-rated stocks among Wall Street analysts. How have VRDN shares performed in 2024? Viridian Therapeutics' stock was trading at $21.78 at the start of the year. Since then, VRDN stock has decreased by 29.3% and is now trading at $15.40. View the best growth stocks for 2024 here. Are investors shorting Viridian Therapeutics? Viridian Therapeutics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 9,470,000 shares, an increase of 24.3% from the March 15th total of 7,620,000 shares. Based on an average daily trading volume, of 962,900 shares, the short-interest ratio is currently 9.8 days. View Viridian Therapeutics' Short Interest. When is Viridian Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our VRDN earnings forecast. How can I listen to Viridian Therapeutics' earnings call? Viridian Therapeutics will be holding an earnings conference call on Wednesday, May 8th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link. How were Viridian Therapeutics' earnings last quarter? Viridian Therapeutics, Inc. (NASDAQ:VRDN) released its quarterly earnings data on Tuesday, February, 27th. The company reported ($1.35) earnings per share for the quarter, missing analysts' consensus estimates of ($0.98) by $0.37. The firm earned $0.07 million during the quarter, compared to the consensus estimate of $0.15 million. Viridian Therapeutics had a negative trailing twelve-month return on equity of 121.80% and a negative net margin of 75,711.48%. The firm's revenue was down 31.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($1.13) earnings per share. Who are Viridian Therapeutics' major shareholders? Viridian Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Rosalind Advisors Inc. (0.48%), Hennion & Walsh Asset Management Inc. (0.17%), Mirae Asset Global Investments Co. Ltd. (0.05%) and Principal Financial Group Inc. (0.02%). Insiders that own company stock include Barrett Katz, Fairmount Funds Management Llc, Jonathan Violin, Lara Meisner, Life Sciences Public F Frazier and Scott Dunseth Myers. View institutional ownership trends. How do I buy shares of Viridian Therapeutics? Shares of VRDN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VRDN) was last updated on 5/5/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldElon to Transform U.S. Economy? Porter & CompanyAutomatic Income (from home)Awesomely, LLCCould Your Accounts Be Frozen?Allegiance GoldThe asset beating inflation by 4xColonial MetalsCharles Payne Demystifies OptionsUnstoppable ProsperityWarren Buffet Stockpiling Gold?Reagan Gold GroupDid You Get Your Free Bitcoin Yet?Crypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viridian Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
